#biotech
Latest news and interesting information about biotech.
ARE faces biotech headwinds
ARE faces biotech headwinds. The company cuts dividends, restructures its portfolio, and makes strategic changes to navigate industry challenges.
Ionis Stock Gains on FDA Approval
Ionis Pharmaceuticals stock gains momentum following FDA approval of REDEMPLO. Financials, pipeline, and growth prospects analyzed.
Cytokinetics SWOT Analysis: Profit Test
Cytokinetics SWOT analysis: biotech stock faces profitability test. Aficamten approval, financial health, and market outlook.
ARK Buys Cerebras Stock, Sells AMD
Cathie Wood's ARK ETF buys Cerebras, Twist Bioscience, and Bullish; sells AMD. Focus on tech and biotech sectors.
HCW Biologics Raises $4M in Private Placement
HCW Biologics completes $4M private placement. Stock surges 112% in a week. E.F. Hutton acted as agent.
Cantor Reiterates Overweight on ORIC Stock
Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.
Assembly Biosciences prices $100M stock offering at $26.50
Assembly Biosciences prices $100 million stock offering at $26.50 per share. Gilead Sciences among investors. Proceeds for clinical development.
Kura Oncology SWOT: Biotech Stock Faces Launch Test
Kura Oncology SWOT analysis: Komzifti launch, financials, analyst ratings, and investment risks covered in detail.
VIR stock gains momentum on partnership and clinical progress
SWOT analysis of Vir Biotechnology: Astellas partnership, VIR-5500 and Hepatitis Delta program progress boost stock. Read on Bond.az.
Belite Bio Stock Rises on NDA Progress
Belite Bio stock rises as H.C. Wainwright reiterates Buy rating and NDA progresses. Tinlarebant potential FDA approval expected in Q1 2027.
Syndax stock gains momentum on strong launch
Syndax Pharmaceuticals stock gains momentum with strong Revuforj launch. Learn about financial performance, pipeline, and market outlook.
Adaptive Biotechnologies CFO Sells $40,619 in Stock
Adaptive Biotechnologies CFO Kyle Piskel sold $40,619 worth of stock to cover tax obligations from RSU vesting.
Biotech at Inflection Point: JPMorgan Covers 14 Firms | Bond.az
JPMorgan covers 14 biotech firms at inflection point, with ratings and price targets. See which companies are poised for growth and the catalysts ahead.
Roivant Sciences stock hits all-time high of $30.35
Roivant Sciences stock hits all-time high of $30.35. The biotech firm surged 156% in a year and beat EPS estimates.
Jupiter Stock Surges on MDMA Therapy Deal
Jupiter Neurosciences stock surges 75.9% on MDMA therapy licensing deal. ALA-002 is a next-generation formulation.
Traws Pharma Gets $8 Price Target from H.C. Wainwright
H.C. Wainwright reaffirms Buy on Traws Pharma with $8 target. Financing secured for influenza drug trial. Read more on Bond.az.
Jefferies Initiates SAB Biotherapeutics with Buy
Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.
RTW Biotech Sets June 11 Annual Meeting
RTW Biotech Opportunities Ltd sets its annual general meeting for June 11, 2026. Details on proxy voting and shareholder information.
First Artificial Egg Created in US
US biotech company Colossal Biosciences creates first artificial eggs, hatching over 30 chicks in Texas. This technology aims to revive extinct species and conserve endangered ones.
Iovance Biotherapeutics: stock gains on melanoma data
Iovance Biotherapeutics stock gains momentum on real-world melanoma data for Amtagvi. Despite losses, analysts see upside from manufacturing efficiencies and label expansion.
Kyntra Bio CEO Buys $19,852 in Stock
Kyntra Bio CEO Thane Wettig buys $19,852 in stock. Analysis on Bond.az.
Pakistani Minister: Without Energy, All Revolutions Will Fail
Pakistani Minister Musadik Masud Malik at WUF13 highlights the importance of energy for revolutions.
Wolfe Research Initiates CytomX Stock with Outperform
Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.
Glenbrook Capital buys $53,486 of SNES shares
Glenbrook Capital Management buys $53,486 worth of SenesTech (SNES) shares. The stock is undervalued with a $10 analyst target.
Norway stocks higher: Oslo OBX up 1.19%
Norway stocks closed higher on Monday, with the Oslo OBX up 1.19% to a 1-month high. Nel ASA and SalMar ASA were among the top gainers.
BioCryst stock: growth path ahead
BioCryst Pharmaceuticals stock analysis: Orladeyo growth, pediatric approval, profitability targets, and pipeline progress.
Cathie Wood's ARK sells AMD stock, buys Cerebras
Cathie Wood's ARK sells AMD stock and buys Cerebras Systems. Daily trading activity for May 15.
Atisama advances RB042 trial, appoints Bernard Coulie as chair
Atisama advances Phase 1 trial of RB042 and appoints Dr. Bernard Coulie as Board Chair. The drug shows safety; higher-dose results due in H2 2026.
Taiwan stocks close lower
Taiwan stock market closed lower on Friday with the Taiwan Weighted index down 1.25%. Sector details and commodity prices included.
Arrowhead director sells $228,333 in stock
Arrowhead Pharmaceuticals director Lu Hongbo sold $228,333 in stock. Shares trade at $79.69 near 52-week high.
...